Group b adenovirus-containing formulation
US-2024398879-A1 · Dec 5, 2024 · US
Selective cell targeting using adenovirus and chemical dimers
US9913866B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9913866-B2 |
| Application number | US-201414485472-A |
| Country | US |
| Kind code | B2 |
| Filing date | Sep 12, 2014 |
| Priority date | Mar 13, 2012 |
| Publication date | Mar 13, 2018 |
| Grant date | Mar 13, 2018 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Compositions and methods for retargeting adenovirus to a cell using chemical dimers are described. In particular, a recombinant adenovirus comprising a nucleic acid comprising a capsid-dimerizing agent binder conjugate and a ligand-dimerizing agent binder conjugate is provided.
First claim
Opening claim text (preview).
The invention claimed is: 1. A recombinant adenovirus comprising a recombinant nucleic acid encoding a capsid-dimerizing agent binder conjugate and a ligand-dimerizing agent binder conjugate, wherein the capsid-dimerizing agent binder conjugate comprises an adenoviral fiber protein and a FRB protein inserted into the H1 loop of the adenoviral fiber protein, and the ligand-dimerizing agent binder conjugate comprises a ligand and a FKBP protein, wherein the FRB protein is encoded by the nucleotide sequence of SEQ ID NO: 69 and the FKBP protein is at least 90% identical to the FKBP protein encoded by SEQ ID NO: 66, and wherein said insertion of the FRB protein into the H1 loop of the adenoviral fiber protein does not inhibit replication and assembly of the adenovirus. 2. The recombinant adenovirus of claim 1 , wherein the ligand is capable of binding a tumor cell. 3. The recombinant adenovirus of claim 1 , wherein the ligand is an antibody. 4. The recombinant adenovirus claim 3 , wherein the antibody is a single domain antibody. 5. The recombinant adenovirus of claim 1 , wherein the FKBP protein is a human FKBP protein. 6. The recombinant adenovirus of claim 5 , wherein the human FKBP protein is FKBP12. 7. A recombinant adenovirus comprising a capsid-dimerizing agent binder conjugate, wherein the capsid-dimerizing agent binder conjugate comprises an adenoviral fiber protein and a FRB protein inserted into the H1 loop of the adenoviral fiber protein, wherein the FRB protein is encoded by the nucleotide sequence of SEQ ID NO: 69, and wherein said insertion of the FRB protein into the H1 loop of the adenoviral fiber protein does not inhibit replication and assembly of the adenovirus. 8. The recombinant adenovirus of claim 7 , wherein the capsid-dimerizing agent binder conjugate is bound to a dimerizing agent. 9. The recombinant adenovirus of claim 8 , wherein the dimerizing agent is further bound to a ligand-dimerizing agent binder conjugate, wherein the ligand-dimerizing agent binder conjugate comprises a ligand and a FKBP protein at least 90% identical to the FKBP protein encoded by SEQ ID NO: 66. 10. The recombinant adenovirus of claim 8 , wherein the dimerizing agent is rapamycin or a rapalog.
Assignees
Inventors
Classifications
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
Antineoplastic agents · CPC title
Viral vectors · CPC title
Special targeting system for viral vectors · CPC title
- A61K35/761Primary
Adenovirus · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9913866B2 cover?
- Compositions and methods for retargeting adenovirus to a cell using chemical dimers are described. In particular, a recombinant adenovirus comprising a nucleic acid comprising a capsid-dimerizing agent binder conjugate and a ligand-dimerizing agent binder conjugate is provided.
- Who is the assignee on this patent?
- Salk Inst For Biological Studi
- What technology area does this patent fall under?
- Primary CPC classification A61K35/761. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Mar 13 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).